(Cannabidiol + hydroxychloroquine) is under clinical development by Incannex Healthcare and currently in Phase I for Lung Disease. According to GlobalData, Phase I drugs for Lung Disease have a 92% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how (Cannabidiol + hydroxychloroquine)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Cannabidiol + hydroxychloroquine) overview

IHL-675A, a fixed combination of cannabidiol and hydroxychloroquine is under development for the treatment of chronic obstructive pulmonary disease (COPD), asthma, bronchitis, colitis, pain and reduced function associated with rheumatoid arthritis, inflammatory bowel disease and other inflammatory lung conditions. It is administered through oral route as soft gel capsules. It was under development for the treatment of sepsis-associated adult respiratory distress syndrome caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 

Incannex Healthcare overview

Incannex Healthcare is a pharmaceutical company. The company offers the development and manufacturing of cannabinoid medicine and therapeutic products. Its product portfolio includes releafia, nutralesic, inflammex, and cannagesia. Incannex Healthcare products are used in the treatment of obstructive sleep apnea, traumatic brain injury, sepsis-associated acute respiratory distress syndrome, and temporomandibular joint dysfunction. It also provides clinical trials and research and development services. It operates in Australia and New Zealand. Incannex Healthcare is headquartered in Melbourne, Victoria, Australia.

For a complete picture of (Cannabidiol + hydroxychloroquine)’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.